Using mHealth to Improve Adherence and Reduce Blood Pressure in Individuals With Hypertension and Mood Disorders.
This proposed 2-stage randomized controlled trial (RCT) will evaluate a personalized patient-centered adherence intervention iTAB-CV + Self-Monitoring (iTAB-CV + SM) vs. Self-Monitoring (SM) alone in poorly adherent hypertensive persons with BD or MDD. This practical, technology-facilitated intervention has potential to improve adherence to antihypertensive medication and reduce SBP among high-risk individuals. The intervention is suitable for primary care or mental health settings and has potential for broad scale-up.
• Age range: from 21 to 80
• Have a clinical diagnosis of either Bipolar Disorder or Major Depressive Disorder as determined by a standardized diagnostic interview, the Mini-International Neuropsychiatric Interview (MINI)
• Have elevated systolic blood pressure ≥130 at screening at least 2 different times during the screening period
• Have received a diagnosis of hypertension per patient self-report at least 6 months prior to enrollment
• Have been prescribed at least one regularly scheduled antihypertensive medicine for 3 or more months since diagnosis
• Have difficulty with adherence to prescribed antihypertensive medication currently or in the past based on one of the following questions: Do you ever miss doses of your prescribed medications for high blood pressure? Or b. Do you ever try to manage your high blood pressure on your own without medication?
• For those with MDD, currently being prescribed an antidepressant medication
• Have their own cellular phone in order to receive text messages as part of the intervention